Indian Journal of Nuclear Medicine

: 2018  |  Volume : 33  |  Issue : 4  |  Page : 317--325

Nonspecific uptake of 68Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature

Dharmender Malik1, Apurva Sood1, Bhagwant Rai Mittal1, Harmandeep Singh1, Rajender Kumar Basher1, Jaya Shukla1, Anish Bhattacharya1, Shrawan Kumar Singh2,  
1 Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Bhagwant Rai Mittal
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012


68Ga-labeled prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography imaging (PET/CT) is a rapidly evolving imaging modality for prostate cancer. Many studies have proved its superiority in staging, restaging, and detecting the recurrent prostate cancer. However, case reports describing the incidental tracer uptake in benign and nonprostatic malignancies are also reported in the literature, thus questioning the specificity of the tracer. This pictorial assay illustrates the nonspecific tracer uptake encountered during PSMA PET/CT imaging, knowledge of which can increase the confidence of interpreting physicians and may also open a new path for peptide receptor radionuclide therapy in nonprostatic malignancies.

How to cite this article:
Malik D, Sood A, Mittal BR, Singh H, Basher RK, Shukla J, Bhattacharya A, Singh SK. Nonspecific uptake of 68Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature.Indian J Nucl Med 2018;33:317-325

How to cite this URL:
Malik D, Sood A, Mittal BR, Singh H, Basher RK, Shukla J, Bhattacharya A, Singh SK. Nonspecific uptake of 68Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature. Indian J Nucl Med [serial online] 2018 [cited 2021 Dec 4 ];33:317-325
Available from:

Full Text


Prostate-specific membrane antigen (PSMA) a type II transmembrane glycoprotein is overexpressed in prostate cancer which further increases manifold with tumor grade and stage.[1] The level of PSMA expression increases with tumor dedifferentiation, metastatic disease, and hormone resistance.[2] PSMA was initially detected in the prostate gland, hence the name. However, eventual histopathological studies have shown its expression in salivary glands, duodenal epithelium, lacrimal glands, proximal tubule cells in the kidney, and tumor-associated vascular endothelium.[3],[4] It is known that PSMA participates in matrix degradation and facilitates integrin signaling and p21-activated kinase activation causing tumor invasion. Role of PSMA in regulating angiogenesis has been postulated; however, its exact mechanism is unknown.[5]

The development of PSMA-targeted small molecule labeled with 68Ga has allowed the molecular imaging of prostate cancer by positron emission tomography (PET). 68Ga-labeled PSMA (also known as 68Ga-PSMA-HBED-CC) since its introduction in the year 2011 has revolutionized the imaging and management of prostate cancer.[6] It is now being increasingly used for whole-body primary staging of intermediate- or high-risk prostate cancer or restaging after biochemical evidence of recurrence (rising prostate-specific antigen levels) in patients with prior radical prostatectomy and/or after radical external beam radiation.[7],[8] Perera et al. in a meta-analysis showed that 68Ga-labeled PSMA PET/computed tomography (CT) in advanced prostate cancer had a sensitivity of 80% and specificity of 97% on per lesion analysis.[9] For overall bone involvement in patients with prostate cancer, the sensitivity and specificity have been found to be 99%–100% and 88%–100%, respectively.[10] However, with increasing experience of imaging with PSMA-labeled radiotracers, expression of PSMA has been demonstrated in various nonprostatic malignant and nonmalignant conditions leading to potential pitfalls in the interpretation of PSMA-targeted imaging. Nevertheless, this drawback may prove beneficial in imaging and therapeutic target for other nonprostatic conditions. Here, we present a few cases showing PSMA expression in unexpected sites encountered during 68Ga-labeled PSMA PET/CT imaging.

 Benign Diseases


68Ga-labeled PSMA normally does not show tracer uptake in the normal brain parenchyma providing high precision for the detection of brain metastasis from prostate cancer.[6] Focal 68Ga-PSMA avidity has been reported in few isolated case reports in meningiomas in the past. This tracer uptake may be either due to the PSMA expression in the tumor vasculature or due to the blood pool effect.[11] Although brain metastases from prostate cancer is a rare occurrence, 68Ga-PSMA uptake in the brain should be interpreted with caution and should be correlated with CT/magnetic resonance imaging findings [Figure 1].{Figure 1}

Cerebral infarct/hemorrhage

68Ga-labeled PSMA PET/CT provides excellent diagnostic value in the detection of brain metastasis and primary brain tumors, as normal brain parenchyma essentially shows no PSMA tracer uptake in the presence of an intact blood–brain barrier.[12] However, breach in blood–brain barrier may lead to nonspecific tracer accumulation in infarct/hemorrhage site due to increased permeability of tracer as well as the simultaneous occurrence of reparative processes (characterized by neovascularization) at these sites.[13] Hence, visualization of tracer avidity in subacute cerebral infarction on PSMA PET/CT may potentially mimic the brain metastasis [Figure 2].{Figure 2}

Lung consolidation

68Ga-PSMA uptake in lung parenchyma has been documented in metastases from prostate cancer and nonprostate malignancies, primary lung cancer, and benign etiologies such as tuberculosis, sarcoidosis, anthracosilicosis, benign lung opacities, and bronchiectasis.[14],[15],[16],[17],[18] Although tracer uptake in the nonprostatic malignancies has been attributed to PSMA expression in the tumor neovasculature endothelial cells, uptake in the benign pathologies is likely due to increased capillary permeability caused by infection or inflammation leading to tracer accumulation in the interstitial space. Thus, cautious interpretation of the scan is required, especially in India where infective pathologies such as tuberculosis are endemic which may lead to over staging of the disease [Figure 3].{Figure 3}


Androgen deprivation therapy is therapeutic treatment for asymptomatic high risk, locally advanced prostate cancer given in isolation or combined with external beam radiotherapy. Androgen deprivation either by medical or surgical castration is known to cause gynecomastia with an incidence as high as 75%. Gynecomastia is the result of an imbalance between estrogens and androgens in breast tissue with a high level of estrogen causing the growth of the breast tissue.[19],[20] Although localization of 68Ga-labeled PSMA in the breast parenchyma has been well documented in the neovasculature of breast cancer, it is essential to know that PSMA expression is also seen in gynecomastia [Figure 4].[21],[22]{Figure 4}

Inferior vena cava thrombus

Prostate cancer is associated with increased risk of thromboembolic disease. The risk of thromboembolic disease increases exponentially with age, and the patient on hormonal therapy has the highest risk of the thromboembolic event.[23] PSMA uptake in thrombi are likely caused by nonspecific tracer binding and are in the part of noise related [Figure 5].[24]{Figure 5}

The rapidly expanding role of 68Ga-labeled PSMA PET/CT in prostate cancer needs careful evaluation as its specificity is limited by some false-positive findings as enumerated in the present article [Table 1].[25],[26],[27],[28],[29],[30],[31],[32],[33],[34],[35],[36],[37],[38],[39],[40],[41],[42],[43] Knowledge of these limitations can decrease the potential diagnostic pitfalls and increase the confidence of interpreting physicians.{Table 1}

 Malignant Diseases

With the rapid evolution of PET from a pure research tool to an imaging modality with enormous clinical potential, especially in oncology, 18F-fluorodeoxyglucose (FDG) an analog of glucose metabolism has been increasingly used for the staging and restaging of most of the solid tumors. Although most of the solid tumors are FDG avidity, some tumors such as prostate cancer, well-differentiated neuroendocrine tumor, renal cell carcinoma (RCC), hepatocellular carcinoma, and low-grade lymphoma shows low FDG avidity.[44] More clinical research led to the development of various other non-FDG avid tracers. 68Ga easily available from Ge-68/Ga-68 generator was labeled with various peptides and used for imaging of neuroendocrine tumors and prostate cancer, etc. 68Ga-labeled PSMA PET/CT is now considered as the reference standard for prostate cancer imaging.[9],[10] As the experience with 68Ga-labeled PSMA PET/CT for prostate imaging is increasing its nonspecific uptake at the other malignancies apart from prostate cancer are being reported. Several isolated case reports have shown incidental PSMA avidity in high-grade gliomas, lung cancer, breast cancer, multiple myeloma, and malignant melanoma, etc. [Table 2].[21],[45],[46],[47],[48],[49],[50],[51],[52],[53],[54],[55],[56],[57],[58],[59],[60],[61],[62],[63],[64],[65],[66] The 68Ga-labeled PSMA avidity in these various nonprostatic malignancies has been ascribed to the PSMA expression in the endothelial cells of the tumor neovasculature.{Table 2}

Focal PSMA accumulation at unexpected places needs careful evaluation, as observed in the present series, incidental focal PSMA avidity in the rectum [Figure 6], and thyroid gland [Figure 7]. Histopathological examination of these lesions revealed adenocarcinoma of the rectum and papillary thyroid cancer, respectively. The authors have already reported few other malignancies such as radioactive iodine-refractory thyroid cancer, gastroesophageal carcinoma, signet ring cell, and urinary bladder carcinoma showing PSMA avidity.[51],[53]{Figure 6}{Figure 7}

Among nonprostate cancers studied by 68Ga-labeled PSMA PET/CT, RCC is by far the most abundant entity. Of the published isolated case reports, 68Ga-labeled PSMA PET/CT is found to be superior in terms of lesion detection in comparison to FDG PET/CT and conventional imaging.[67] Moreover, PSMA provides a definite advantage over FDG in the detection of brain metastasis due to the absence of tracer uptake in normal brain parenchyma [Figure 8]. The finding of PSMA expression in these malignancies provides interesting diagnostic and radioligand-based therapeutic options.{Figure 8}


68Ga-labeled PSMA PET/CT is generally considered to be highly sensitive and specific for the prostate cancer, but PSMA, as publicized earlier, is not an exclusive marker of prostate cancer. A growing number of reports and present pictorial assay indicate the possibility of false-positive PSMA accumulation in various nonprostatic benign and malignant pathologies. Knowledge of the false-positive tracer uptake of 68Ga-labeled PSMA helps in improving the reporting of 68Ga-PSMA for prostate cancer imaging. Despite the reports on false-positive tracer uptake in nonprostate conditions, 68Ga-labeled PSMA is the most accurate tracer available for imaging prostate cancer. This nonexclusivity of PSMA avidity opens a window to utilize the variety of accessible radioactive PSMA ligands for imaging and possibility of nuclear theranostic in a few other nonprostate malignancies.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest


1Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998;82:2256-61.
2DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-64.
3Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
4Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-81.
5Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006;26:5310-24.
6Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40:486-95.
7Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: Version 1.0. Eur J Nucl Med Mol Imaging 2017;44:1014-24.
8Kallur KG, Ramachandra PG, Rajkumar K, Swamy SS, Desai I, Rao RM, et al. Clinical utility of gallium-68 PSMA PET/CT scan for prostate cancer. Indian J Nucl Med 2017;32:110-7.
9Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A Systematic review and meta-analysis. Eur Urol 2016;70:926-37.
10Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:2114-21.
11Bilgin R, Ergül N, Çermik TF. Incidental meningioma mimicking metastasis of prostate adenocarcinoma in 68Ga-labeled PSMA ligand PET/CT. Clin Nucl Med 2016;41:956-8.
12Sasikumar A, Joy A, Pillai MR, Nanabala R, Anees K M, Jayaprakash PG, et al. Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors-preliminary analysis. Clin Nucl Med 2017;42:e41-8.
13Prakash R, Carmichael ST. Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury. Curr Opin Neurol 2015;28:556-64.
14Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: Clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 2018;38:200-17.
15Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging 2017;44:2117-36.
16McGuiness M, Sounness B. 68Ga-PSMA-ligand PET/CT uptake in anthracosilicosis. Clin Nucl Med 2017;42:e431-2.
17Bouchelouche K, Vendelbo MH. Pulmonary opacities and bronchiectasis avid on 68Ga-PSMA PET. Clin Nucl Med 2017;42:e216-7.
18Ahuja A, Taneja S, Thorat K, Jena A. 68Ga-prostate-specific membrane antigen-avid tubercular lesions mimicking prostate cancer metastasis on simultaneous prostate-specific membrane antigen PET/MRI. Clin Nucl Med 2017;42:e509-10.
19Dobs A, Darkes MJ. Incidence and management of gynecomastia in men treated for prostate cancer. J Urol 2005;174:1737-42.
20Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-79.
21Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart J, Maes A, et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging 2017;44:689-94.
22Sasikumar A, Joy A, Nair BP, Pillai MRA, Madhavan J. False positive uptake in bilateral gynecomastia on 68Ga-PSMA PET/CT scan. Clin Nucl Med 2017;42:e412-4.
23Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, et al. Risk of thromboembolic diseases in men with prostate cancer: Results from the population-based PCBaSe Sweden. Lancet Oncol 2010;11:450-8.
24Derlin T, Thiele J, Weiberg D, Thackeray JT, Püschel K, Wester HJ, et al. Evaluation of 68Ga-glutamate carboxypeptidase II ligand positron emission tomography for clinical molecular imaging of atherosclerotic plaque neovascularization. Arterioscler Thromb Vasc Biol 2016;36:2213-9.
25Jain TK, Jois AG, Kumar V S, Singh SK, Kumar R, Mittal BR, et al. Incidental detection of tracer avidity in meningioma in 68Ga-PSMA PET/CT during initial staging for prostate cancer. Rev Esp Med Nucl Imagen Mol 2017;36:133-4.
26Noto B, Vrachimis A, Schäfers M, Stegger L, Rahbar K. Subacute stroke mimicking cerebral metastasis in 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med 2016;41:e449-51.
27Vadi SK, Kumar R, Singh H, Singh SK, Mittal BR. 68Ga-prostate-specific membrane antigen expression in neurocysticercosis lesions in a patient with prostate carcinoma. Clin Nucl Med 2018;43:e122-4.
28Kanthan GL, Drummond J, Schembri GP, Izard MA, Hsiao E. Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016;41:331-2.
29Elri T, Aras M, Salihoglu YS, Erdemir RU, Cabuk M. A potential pitfall in the use of 68Ga-PSMA PET/CT: Anthracosis. Rev Esp Med Nucl Imagen Mol 2017;36:65-6.
30Pyka T, Weirich G, Einspieler I, Maurer T, Theisen J, Hatzichristodoulou G, et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med 2016;57:367-71.
31Malik D, Basher RK, Mittal BR, Jain TK, Bal A, Singh SK, et al. 68Ga-PSMA expression in pseudoangiomatous stromal hyperplasia of the breast. Clin Nucl Med 2017;42:58-60.
32Bhardwaj H, Stephens M, Bhatt M, Thomas PA. Prostate-specific membrane antigen PET/CT findings for hepatic hemangioma. Clin Nucl Med 2016;41:968-9.
33Hermann RM, Djannatian M, Czech N, Nitsche M. Prostate-specific membrane antigen PET/CT: False-positive results due to sarcoidosis? Case Rep Oncol 2016;9:457-63.
34Chan M, Schembri GP, Hsiao E. Serous cystadenoma of the pancreas showing uptake on 68Ga PSMA PET/CT. Clin Nucl Med 2017;42:56-7.
35Kobe C, Maintz D, Fischer T, Drzezga A, Chang DH. Prostate-specific membrane antigen PET/CT in splenic sarcoidosis. Clin Nucl Med 2015;40:897-8.
36Law WP, Fiumara F, Fong W, Miles KA. Gallium-68 PSMA uptake in adrenal adenoma. J Med Imaging Radiat Oncol 2016;60:514-7.
37Froehner M, Toma M, Zöphel K, Novotny V, Laniado M, Wirth MP, et al. PSMA-PET/CT-positive Paget disease in a patient with newly diagnosed prostate cancer: Imaging and bone biopsy findings. Case Rep Urol 2017;2017:1654231.
38De Coster L, Sciot R, Everaerts W, Gheysens O, Verscuren R, Deroose CM, et al. Fibrous dysplasia mimicking bone metastasis on 68Ga-PSMA PET/MRI. Eur J Nucl Med Mol Imaging 2017;44:1607-8.
39Vamadevan S, Le K, Bui C, Mansberg R. Incidental PSMA uptake in an undisplaced fracture of a vertebral body. Clin Nucl Med 2017;42:465-6.
40Kanthan GL, Hsiao E, Kneebone A, Eade T, Schembri GP. Desmoid tumor showing intense uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016;41:508-9.
41Zacho HD, Nielsen JB, Dettmann K, Hjulskov SH, Petersen LJ. 68Ga-PSMA PET/CT uptake in intramuscular Myxoma imitates prostate cancer metastasis. Clin Nucl Med 2017;42:487-8.
42Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Singh SK. Incidental detection of tracer avidity in liposarcoma on 68Ga-labelled Prostate specific membrane antigen PET/CT. Clin Nucl Med 2018;43:e334-e335.
43Vamadevan S, Le K, Shen L, Ha L, Mansberg R. Incidental prostate-specific membrane antigen uptake in a peripheral nerve sheath tumor. Clin Nucl Med 2017;42:560-2.
44Flavell RR, Naeger DM, Aparici CM, Hawkins RA, Pampaloni MH, Behr SC, et al. Malignancies with low fluorodeoxyglucose uptake at PET/CT: Pitfalls and prognostic importance: Resident and fellow education feature. Radiographics 2016;36:293-4.
45Fragomeni RA, Menke JR, Holdhoff M, Ferrigno C, Laterra JJ, Solnes LB, et al. Prostate-specific membrane antigen–targeted imaging with [18F]DCFPyL in high-grade gliomas. Clin Nuc Med 2017;42:e433–e435.
46Sager S, Vatankulu B, Uslu L, Sönmezoglu K. Incidental detection of follicular thyroid carcinoma in 68Ga-PSMA PET/CT imaging. J Nucl Med Technol 2016;44:199-200.
47Jena A, Zaidi S, Kashyap V, Jha A, Taneja S. PSMA expression in multinodular thyroid neoplasm on simultaneous ga-68-PSMA PET/MRI. Indian J Nucl Med 2017;32:159-61.
48Arora S, Damle NA, Parida GK, Singhal A, Nalli H, Dattagupta S, et al. Recurrent medullary thyroid carcinoma on 68Ga-prostate-specific membrane antigen PET/CT: Exploring new theranostic avenues. Clin Nucl Med 2018;43:359-60.
49Krishnaraju VS, Basher RK, Singh H, Singh SK, Bal A, Mittal BR, et al. Incidental detection of type B2 thymoma on 68Ga-labeled prostate-specific membrane antigen PET/CT imaging. Clin Nucl Med 2018;43:356-8.
50Shetty D, Loh H, Bui C, Mansberg R, Stevanovic A. Elevated 68Ga prostate-specific membrane antigen activity in metastatic non-small cell lung cancer. Clin Nucl Med 2016;41:414-6.
51Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Singh SK, et al. 68Ga-labeled PSMA uptake in nonprostatic malignancies: Has the time come to remove “PS” from PSMA? Clin Nucl Med 2018;43:529-32.
52Noto B, Weckesser M, Buerke B, Pixberg M, Avramovic N. Gastrointestinal stromal tumor showing intense tracer uptake on PSMA PET/CT. Clin Nucl Med 2017;42:200-2.
53Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Sood A, et al. 68Ga-labelled PSMA (prostate specific membrane antigen) expression in signet-ring cell gastric carcinoma. Eur J Nucl Med Mol Imaging 2018;45:1276-7.
54Stoykow C, Huber-Schumacher S, Almanasreh N, Jilg C, Ruf J. Strong PSMA radioligand uptake by rectal carcinoma: Who put the “S” in PSMA? Clin Nucl Med 2017;42:225-6.
55Sasikumar A, Joy A, Nanabala R, Pillai MR, Thomas B, Vikraman KR, et al. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016;43:795-6.
56Alipour R, Gupta S, Trethewey S. 68Ga-PSMA uptake in combined hepatocellular cholangiocarcinoma with skeletal metastases. Clin Nucl Med 2017;42:e452-3.
57Vamadevan S, Shetty D, Le K, Bui C, Mansberg R, Loh H, et al. Prostate-specific membrane antigen (PSMA) avid pancreatic neuroendocrine tumor. Clin Nucl Med 2016;41:804-6.
58Arora S, Damle NA, Aggarwal S, Passah A, Behera A, Arora G, et al. Prostate-specific membrane antigen expression in adrenocortical carcinoma on 68Ga-prostate-specific membrane antigen PET/CT. Clin Nucl Med 2018;43:449-51.
59Rhee H, Blazak J, Tham CM, Ng KL, Shepherd B, Lawson M, et al. Pilot study: Use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res 2016;6:76.
60Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: Initial experience. Eur J Nucl Med Mol Imaging 2017;44:102-7.
61Roy SG, Parida GK, Tripathy S, Singhal A, Tripathi M, Bal C, et al. In vivo demonstration of PSMA expression in adenocarcinoma urinary bladder using 68Ga-PSMA 11 PET/CT. Clin Nucl Med 2017;42:542-3.
62Sasikumar A, Joy A, Pillai MRA, Alex TM, Narayanan G. 68Ga-PSMA PET/CT in osteosarcoma in fibrous dysplasia. Clin Nucl Med 2017;42:446-7.
63Osman MM, Iravani A, Hicks RJ, Hofman MS. Detection of synchronous primary malignancies with 68Ga-labeled prostate-specific membrane antigen PET/CT in patients with prostate cancer: Frequency in 764 patients. J Nucl Med 2017;58:1938-42.
64Rauscher I, Maurer T, Steiger K, Schwaiger M, Eiber M. Image of the month: Multifocal 68Ga prostate-specific membrane antigen ligand uptake in the skeleton in a man with both prostate cancer and multiple myeloma. Clin Nucl Med 2017;42:547-8.
65Anconina R, Hod N, Levin D, Ezroh Kazap D, Lantsberg S. Incidental detection of metastatic malignant melanoma on 68Ga-prostate-specific membrane antigen PET/CT imaging: Correlative imaging with FDG PET/CT and review of the literature. Clin Nucl Med 2018;43:204-6.
66Froehner M, Kuithan F, Zöphel K, Heberling U, Laniado M, Wirth MP. Prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography and immunohisto-chemical findings in a patient with synchronous metastatic penile and prostate cancer. Urology 2017;101:e5-6.
67Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, Bögemann M, et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging 2018;45:860-77.